Search Results - Raghavendra Devadiga

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophi... by Amit Bhavsar, Janusz Zaryczański, Anna Wasilewska, Delphine Saragoussi, Raghavendra Devadiga, Chris Colby, Enas Bahar, Jacek Wysocki

    Published in Human Vaccines & Immunotherapeutics (2022-11-01)
    Get full text
    Article


  2. 2

    Post-marketing surveillance to assess the safety and tolerability of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) in Korean chi... by Soon Min Lee, Sung Jin Kim, Jing Chen, Rok Song, Joon-Hyung Kim, Raghavendra Devadiga, Yun-Kyung Kim

    Published in Human Vaccines & Immunotherapeutics (2019-05-01)
    Get full text
    Article


  3. 3

    Trends in all-cause pneumonia and otitis media in children aged &lt;2 years following pneumococcal conjugate vaccine introduction in Colombia by Gabriel Carrasquilla, Alexandra Porras-Ramírez, Sandra Martinez, Rodrigo DeAntonio, Raghavendra Devadiga, Carla Talarico, Diana C. Caceres, Maria M. Castrejon, Patricia Juliao

    Published in Human Vaccines & Immunotherapeutics (2021-04-01)
    Get full text
    Article


  4. 4

    A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea by Soon Min Lee, Jang Hoon Lee, Eun Song Song, Sung Jin Kim, Joon Hyung Kim, Rupert W. Jakes, Raghavendra Devadiga, Moon Sung Park

    Published in Human Vaccines & Immunotherapeutics (2018-12-01)
    Get full text
    Article


Search Tools: